An AI-powered tool helped patients make more confident, personalized decisions about knee replacement surgery—and led to ...
M is positioned as the first oral antiviral sugar chemistry drug BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the 'Company”), a clinical stage biotechnology ...
Enrollment is complete for the randomized part of ENHANCE, a Phase 3 trial testing a new dosing schedule for Briumvi in ...
The findings underscore the need to explore alternative therapeutic approaches to managing persistent symptoms, the authors ...
News-Medical.Net on MSN
Landmark trial shows drug-eluting balloon as effective option for in-stent restenosis
Results from the first randomized clinical trial in the United States to compare a sirolimus-eluting balloon (DEB) to control ...
MedPage Today on MSN
Trial Questions Ketamine Use for Patients Hospitalized With Depression
A 2022 study showed that 28.3% of patients receiving ketamine had a billing diagnosis of depression. McLoughlin's group ...
COVID-19 mRNA vaccines may do more than just protect against the coronavirus - they may also help the body fight cancer. In ...
News-Medical.Net on MSN
Repeated ketamine infusions offer no extra benefit for people hospitalized with depression
Findings from a randomized and blinded clinical trial investigating repeated ketamine infusions for treating depression have ...
1d
BIOXYTRAN, INC.: Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug
M is positioned as the first oral antiviral sugar chemistry drug BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback